STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Sutro Biopharma to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Sutro Biopharma (NASDAQ: STRO), a company specializing in antibody drug conjugates (ADCs) for oncology, has announced its participation in two upcoming investor conferences. The company will present at The Citizens Life Sciences Conference in New York from May 7-8, 2025, and the BofA Securities 2025 Health Care Conference in Las Vegas from May 13-15, 2025. Webcasts of both presentations will be available on Sutro's website investor relations section, with replays accessible for at least 30 days after each event.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

+2.80% News Effect

On the day this news was published, STRO gained 2.80%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences.

Conference Details:

The Citizens Life Sciences Conference
Date: May 7-8, 2025
Location: New York, NY

BofA Securities 2025 Health Care Conference
Date: May 13-15, 2025
Location: Las Vegas, NV

Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the Company’s website at www.sutrobio.com. Archived replays will be available for at least 30 days after the event.

About Sutro Biopharma
Sutro Biopharma, Inc., is relentlessly focused on the discovery and development of precisely designed cancer therapeutics to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro is advancing a robust early-stage pipeline of novel exatecan and dual-payload antibody drug conjugates (ADCs), coupled with high-value collaborations and industry partnerships, which validate its continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com

Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com


FAQ

What investor conferences will Sutro Biopharma (STRO) attend in May 2025?

Sutro Biopharma will attend The Citizens Life Sciences Conference (May 7-8) in New York and the BofA Securities 2025 Health Care Conference (May 13-15) in Las Vegas.

How can investors access Sutro Biopharma's (STRO) conference presentations?

Investors can access the webcasts through the News & Events page of Sutro's Investor Relations section at www.sutrobio.com, with replays available for at least 30 days after each event.

What is Sutro Biopharma's (STRO) main business focus?

Sutro Biopharma is an oncology company that specializes in pioneering site-specific and novel-format antibody drug conjugates (ADCs).

Where will the BofA Securities 2025 Health Care Conference featuring Sutro Biopharma take place?

The BofA Securities 2025 Health Care Conference will take place in Las Vegas, NV from May 13-15, 2025.
Sutro Biopharma

NASDAQ:STRO

STRO Rankings

STRO Latest News

STRO Latest SEC Filings

STRO Stock Data

79.91M
8.12M
4.6%
62.93%
3.67%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO